ReviewChembiochem : a European journal of chemical biology2025
Development and Recent Advances in SLIPT-PM: A Chemogenetic Platform for Manipulating Signaling at the Plasma Membrane.
Review in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Upon cell stimulation, mammalian cells activate various signaling proteins and lipids by recruiting their upstream regulators to the inner leaflet of the plasma membrane (PM), which in turn determines their cellular response. Therefore, artificially inducing protein translocation to the PM is an effective strategy for dissecting cell signaling networks and engineering cellular functions. Self-localizing ligand-induced protein translocation (SLIPT) is an emerging technique that we developed to control protein localization in living cells using synthetic self-localizing ligands (SLs). Building on this strategy, we recently introduced a versatile chemogenetic SLIPT platform that rapidly recruits proteins of interest fused to an engineered Escherichia coli dihydrofolate reductase tag from the cytoplasm to the PM using a trimethoprim-based SL. The PM-specific SLIPT (SLIPT-PM) system is easy to use and enables researchers to manipulate diverse intracellular signaling molecules and pathways with controlled reversibility and repeatability. Owing to its modular design, related SLIPT-PM tools have also been developed to support more sophisticated experiments, such as light-induced spatially regulated protein recruitment and multiplexed signal manipulation. In this concept article, we review the development, principal features, current applications, and future challenges of SLIPT-PM as a unique tool in chemical biology and synthetic biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.